Vivanza Biosci.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE984E01035
  • NSEID:
  • BSEID: 530057
INR
1.72
-0.14 (-7.53%)
BSENSE

Jun 18

BSE+NSE Vol: 514

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Beryl Drugs
Vivanza Biosci.
Unjha Formul.
Brawn Biotech
Decipher Labs
Ortin Global
Genomic Valley
Ganga Pharma.
Shyama Computro.
Fabino Enter
Saroja Pharma In
Why is Vivanza Biosciences Ltd ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 9.99% of over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 7.56 times
2
Stock is technically in a Mildly Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 19-May-26 and has generated -3.8% returns since then
  • Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
3
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 0.10% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -35.16% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vivanza Biosci. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Vivanza Biosci.
-20.0%
-0.77
45.38%
Sensex
-5.34%
-0.49
12.94%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
63.57%
EBIT Growth (5y)
9.99%
EBIT to Interest (avg)
0.39
Debt to EBITDA (avg)
1.66
Net Debt to Equity (avg)
2.32
Sales to Capital Employed (avg)
2.74
Tax Ratio
27.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
3.96%
ROE (avg)
10.64%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
19
Industry P/E
32
Price to Book Value
1.71
EV to EBIT
17.56
EV to EBITDA
17.56
EV to Capital Employed
1.21
EV to Sales
0.15
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
4.90%
ROE (Latest)
9.17%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
NET SALES(Latest six months)

At Rs 51.61 cr has Grown at 2,506.57%

PAT(9M)

Higher at Rs 0.31 Cr

DEBTORS TURNOVER RATIO(HY)

Highest at 9.36 times

-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 0.07 cr

Loading Valuation Snapshot...
Here's what is working for Vivanza Biosci.
Net Sales - Latest six months
At Rs 51.61 cr has Grown at 2,506.57%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Debtors Turnover Ratio- Half Yearly
Highest at 9.36 times
in the last five half yearly periods
MOJO Watch
Company has been able to settle its Debtors faster

Debtors Turnover Ratio

Profit After Tax (PAT) - Nine Monthly
Higher at Rs 0.31 Cr
than preceding 12 month period ended Mar 2026 of Rs -0.85 cr
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Vivanza Biosci.
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 0.07 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents